Access 2 Verified Employees Profiles for Senya TherapeuticsUnlock Free Contacts Now
About
Developing first-in-class LRG inhibitor to harness pathogenic effect of TGF-β cascade in chronic kidney disease and cancer | a spin-out from University College London